Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

This case report describes a rare occurrence of injection site reactions in a 77-year-old woman with eosinophilic fasciitis using subcutaneous methotrexate, marking the first documented instance in this patient population.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.

This review found topical ketoconazole to be highly effective against Malassezia-related skin conditions, though other treatments may outperform it for Tinea and Candida infections.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

This study found that intralesional triamcinolone was the most effective treatment for achieving over 50% hair regrowth in alopecia areata patients, especially those with single patches.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study found that 308 nm excimer lamp therapy provides a good clinical response with fewer adverse effects for limited alopecia areata but is less effective for widespread hair loss like alopecia totalis.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This report describes a case where the JAK inhibitor tofacitinib led to hair regrowth in a patient with alopecia totalis but also worsened facial acne, highlighting a unique adverse effect.

This study observed that intradermal injections of Betamethasone were more effective than topical Clobetazole for treating alopecia areata in children, while Tofacitinib showed higher efficacy in those with atopic dermatitis.

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

This study found that methotrexate treatment for 15 days suppressed tuberculin hypersensitivity in Strain 2 guinea pigs without causing lymphopenic or anti-inflammatory effects.

This study observes that TYK2 inhibition with BMS-986202 may extend hair follicle growth phases and decrease inflammatory cell markers in alopecia areata, suggesting potential for clinical application.

This study found that applying amaranthus extract cream to the scalp significantly improved terminal hair density, anagen hair count, and pilary index in men with male pattern hair loss, suggesting it may be a safe and effective supportive therapy.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study suggests that autologous micrograft technology may be more effective than finasteride in promoting hair growth in patients with androgenetic alopecia.

Enhancing Tregs can protect against alopecia areata.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.